Would you consider adding abiraterone, in addition to ADT, for patients with less than very-high risk localized prostate cancer but high clinical-genomic metastasis risk after EBRT?

This is a very tricky area to be sure. The short answer is yes, I do in carefully selected patients.

It is well established that genomics correlates with biology in the mHSPC and mCRPC settings. Now, there is emerging data that genomics correlates well with biology in the localized disease setting (e...